Latest Safety News

Global Uranium and Enrichment Limited has completed a scoping study for its Hansen Deposit in Colorado, revealing strong economic potential through innovative mining and beneficiation methods.

Silex Systems reports steady progress on its TRL-6 uranium enrichment demonstration, targeting completion by end-2025, while securing initial US government funding to support commercialisation efforts.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Lefroy Exploration has kicked off a major grade control drilling campaign at its Lucky Strike Gold Project, fully funded by partner BML Ventures, aiming to underpin mining operations slated for the second half of 2025.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Critica Limited has secured drilling approvals and government funding to explore high-grade heavy rare earth elements at its Aurora and Juno satellite prospects near the flagship Jupiter deposit in Western Australia.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

MinRex Resources has secured all approvals to commence a fully funded drilling program targeting high-priority copper-gold deposits at the Fraser Range Project in Western Australia, aiming to unlock significant exploration potential.

Neurizon Therapeutics has announced the successful completion of its Open-Label Extension study for NUZ-001 in ALS, revealing significant survival benefits and strong tolerability. The company is on track to release top-line results in Q3 2025 and advance to a pivotal Phase 2/3 trial.

Boom Logistics reports robust 3Q FY25 results with revenue and profit gains led by renewables projects, while pausing its share buy-back after meeting targets.

Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.